MRD-guided ibrutinib plus venetoclax improves outcomes in CLL patients with TP53, ATM, or NOTCH1 aberrations compared to ibrutinib and FCR: Results from the Phase III NCRI FLAIR trial
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Surita Dalal, Jane Shingles, Sean Girvan, David Cairns, Paul Glover, Helen Warren, Thomas Grand, Nichola Webster, Andy Rawstron, Darren Newton, Charlotte Evans, Ruth de Tute, Anna Hockaday, Sharon Jackson, Sue Bell, Natasha Greatorex, David Stones, David Allsup, Adrian Bloor, Anita Sarma, Abraham Mullasseril Varghese, Peter Hillmen, Talha Munir
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417008013